Health economic analysis of Breast Cancer Index in patients with ER+, LN- breast cancer.

@article{Gustavsen2013HealthEA,
  title={Health economic analysis of Breast Cancer Index in patients with ER+, LN- breast cancer.},
  author={G. G. Gustavsen and Brock E Schroeder and Patrick A. Kennedy and Kristin Ciriello Pothier and Mark G. Erlander and Catherine A. Schnabel and Haythem Ali},
  journal={The American journal of managed care},
  year={2013},
  volume={20 8},
  pages={
          e302-10
        }
}
OBJECTIVES Breast Cancer Index (BCI) is a novel gene expression-based test for patients with estrogen receptor positive (ER+), lymph node negative (LN-) breast cancer that predicts risk of recurrence over 10 years, and also specifically predicts risk of late (≥5 y) recurrences and likelihood of benefit from extended (≥5 y) endocrine therapy. The objective of this study was to evaluate cost utility of BCI from a US third-party payer perspective. STUDY DESIGN Two fact-based economic models were… CONTINUE READING